GSK plc (LON:GSK – Get Free Report)’s share price reached a new 52-week low on Tuesday . The stock traded as low as GBX 1,360 ($17.50) and last traded at GBX 1,361.14 ($17.52), with a volume of 53444816 shares changing hands. The stock had previously closed at GBX 1,397 ($17.98).
Analyst Ratings Changes
GSK has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($23.81) price target on shares of GSK in a research note on Tuesday, September 3rd. Shore Capital reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Berenberg Bank reissued a “buy” rating and set a GBX 1,820 ($23.42) price objective on shares of GSK in a research note on Tuesday, September 10th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,842.50 ($23.71).
Check Out Our Latest Stock Report on GSK
GSK Trading Down 0.4 %
GSK Announces Dividend
The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.19) per share. This represents a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s dividend payout ratio is presently 5,309.73%.
Insider Transactions at GSK
In other GSK news, insider Jonathan Symonds bought 7,150 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). In other news, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was acquired at an average cost of GBX 2,051 ($26.39) per share, for a total transaction of £9,147.46 ($11,771.28). Also, insider Jonathan Symonds bought 7,150 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($17.94) per share, for a total transaction of £99,671 ($128,260.20). Insiders have acquired 7,604 shares of company stock worth $10,893,038 over the last quarter. 1.61% of the stock is currently owned by insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
- Five stocks we like better than GSK
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Rocket Lab is the Right Stock for the Right Time
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Most Volatile Stocks, What Investors Need to Know
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.